Providing advice & guidance for tech and digital scale up brands to expand internationally & support companies looking to land & expand into the Greater Phoenix region USA

Chris has over 30 years of experience in key sectors such as MedTech devices, Pharma, Bio Pharma, CRO and Academia. He has great access to mission-critical clinical trial and evaluator channels as well as funding, investment, government, and regulatory bodies and networks.

Malcolm is the Lead Partner of Frazier & Deeter UK, a firm providing advisory services to mid-market businesses, with expertise in supporting cross-border businesses. In addition to leading the firm’s growth in the UK, Malcolm is responsible for tax advisory services and transaction advisory services. Malcolm is also the Global Leader of Transfer Pricing Services at Frazier & Deeter.

As a Partner in Frazier & Deeter Tax Practice, David Patton provides tax planning and compliance services to large and middle-market corporate taxpayers. He has worked extensively with taxpayers having multinational operations with cross-border compliance and transaction needs.  

Tony is the CEO of One Nucleus, a membership organisation for international life science and healthcare companies with basis in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.

Mindy is an E-health Practitioner, offering consulting services, commercial strategy, problem solving and storytelling for businesses focused on transformation of healthcare provision, delivery of technology products, services and exit strategies.

Mark has been a leader in Quality and Regulatory for over 25 years. His career includes roles in quality engineering, design assurance, audit, and quality management for companies, including St. Jude Medical and Medtronic, and has provided guidance to numerous medical device and pharmaceutical manufacturers of all sizes.

30 years of experience in the discovery & diagnosis of novel treatments for diseases with unmet medical needs. Formerly at Pfizer, doing research into neurodegenerative diseases in the UK. Subsequently, set up Cambridge Drug Discovery in 1997 and sold it in 2001. Since then, helped to raise £300mln for life sciences companies, and enabled inward investment into the UK of £6bln.

As CEO at US Expansion Partners, David Rose leads a team that helps European technology companies navigate the complexities of launching, managing, and scaling operations in the United States. He has more than 20 years of leadership experience with Fortune 500, high-growth firms and start-up companies in the technology, Internet, and media industries.